参考资料:
[1]. Romero-Clavijo. et al. (2019)Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aaw7999
[2]. Researchers Develop New Class of Lung Cancer Drugs. Retrieved Sep. 19, 2019, from https://www.biospace.com/article/new-class-of-drug-in-combination-shows-promise-for-lung-cancer/
[3]. Could a combo treatment boost KRAS inhibitors in lung cancer?. Retrieved Sep. 19, 2019, from https://www.fiercebiotech.com/research/improving-kras-inhibitors-lung-cancers-a-combo
[4]. Two Is Better Than One: Combining IGF1R and MEK Blockade as a Promising Novel Treatment Strategy Against KRAS-Mutant Lung Cancer. Retrieved Sep. 19, 2019, from https://cancerdiscovery.aacrjournals.org/content/3/5/491.figures-only
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。▽关注【药明康德】微信公众号